A Phase 2 interventional study of Radiation in Glioma, sponsored by Istituto Clinico Humanitas. Completed at 1 site in Italy. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.
Sponsored by Istituto Clinico Humanitas · Phase 2, Interventional, and Treatment
To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG.
Investigators designed this study with the aim to assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG. The potential advantage of this approach is deliver a more selective irradiation to tumor's target with reducing the dose to normal brain and to allow the delivery of a higher dose, optimizing the therapeutic window.
1,425 studies on the registry are indexed under Glioma; 355 are open to participants now.
This study's enrollment of 20 is below the median of 32 across 1,085 interventional studies indexed under Glioma.
Browse Glioma studies →Istituto Clinico Humanitas is the lead sponsor of 279 studies on the registry; 71 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Histologically confirmed HGG after tumor biopsy
Exclusion criteria:
Exclusion Criteria:
-
To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
Radiation: Radiation
hypofractionated IMRT
PFS
Progression free survival
Time frame: one year
OS
Overall Survival
Time frame: one year
Toxicity
Incidence of hematologic and non hematologic severe toxicities (grade III/ IV) will evaluate using NCI-CTCA scale. Late toxicity will evaluate using CTCA 4.2
Time frame: one year
QoL
Quality of Life
Time frame: one year
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.